Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Respiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, despite its importance, no vaccine exists. The chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, M...

Full description

Bibliographic Details
Main Authors: Green, C, Scarselli, E, Sande, C, Thompson, A, de Lara, C, Taylor, K, Haworth, K, Del Sorbo, M, Angus, B, Siani, L, Di Marco, S, Traboni, C, Folgori, A, Colloca, S, Capone, S, Vitelli, A, Cortese, R, Klenerman, P, Nicosia, A, Pollard, A
Format: Journal article
Language:English
Published: American Association for the Advancement of Science 2015
_version_ 1826285379798433792
author Green, C
Scarselli, E
Sande, C
Thompson, A
de Lara, C
Taylor, K
Haworth, K
Del Sorbo, M
Angus, B
Siani, L
Di Marco, S
Traboni, C
Folgori, A
Colloca, S
Capone, S
Vitelli, A
Cortese, R
Klenerman, P
Nicosia, A
Pollard, A
author_facet Green, C
Scarselli, E
Sande, C
Thompson, A
de Lara, C
Taylor, K
Haworth, K
Del Sorbo, M
Angus, B
Siani, L
Di Marco, S
Traboni, C
Folgori, A
Colloca, S
Capone, S
Vitelli, A
Cortese, R
Klenerman, P
Nicosia, A
Pollard, A
author_sort Green, C
collection OXFORD
description Respiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, despite its importance, no vaccine exists. The chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, MVA-RSV, are replication-defective viral vectors encoding the RSV fusion (F), nucleocapsid (N), and matrix (M2-1) proteins for the induction of humoral and cellular responses. We performed an open-label, dose escalation, phase 1 clinical trial in 42 healthy adults in which four different combinations of prime/boost vaccinations were investigated for safety and immunogenicity, including both intramuscular (IM) and intranasal (IN) administration of the adenovirus-vectored vaccine. The vaccines were safe and well tolerated, with the most common reported adverse events being mild injection site reactions. No vaccine-related serious adverse events occurred. RSV neutralizing antibody titers rose in response to IM prime with PanAd3-RSV and after IM boost for individuals primed by the IN route. Circulating anti-F immunoglobulin G (IgG) and IgA antibody-secreting cells (ASCs) were observed after the IM prime and IM boost. RSV-specific T cell responses were increased after the IM PanAd3-RSV prime and were most efficiently boosted by IM MVA-RSV. Interferon-γ (IFN-γ) secretion after boost was from both CD4(+) and CD8(+) T cells, without detectable T helper cell 2 (TH2) cytokines that have been previously associated with immune pathogenesis following exposure to RSV after the formalin-inactivated RSV vaccine. In conclusion, PanAd3-RSV and MVA-RSV are safe and immunogenic in healthy adults. These vaccine candidates warrant further clinical evaluation of efficacy to assess their potential to reduce the burden of RSV disease.
first_indexed 2024-03-07T01:27:56Z
format Journal article
id oxford-uuid:9299f417-4ee8-42be-b5f6-3e30decc9266
institution University of Oxford
language English
last_indexed 2024-03-07T01:27:56Z
publishDate 2015
publisher American Association for the Advancement of Science
record_format dspace
spelling oxford-uuid:9299f417-4ee8-42be-b5f6-3e30decc92662022-03-26T23:26:46ZChimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9299f417-4ee8-42be-b5f6-3e30decc9266EnglishSymplectic Elements at OxfordAmerican Association for the Advancement of Science2015Green, CScarselli, ESande, CThompson, Ade Lara, CTaylor, KHaworth, KDel Sorbo, MAngus, BSiani, LDi Marco, STraboni, CFolgori, AColloca, SCapone, SVitelli, ACortese, RKlenerman, PNicosia, APollard, ARespiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, despite its importance, no vaccine exists. The chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, MVA-RSV, are replication-defective viral vectors encoding the RSV fusion (F), nucleocapsid (N), and matrix (M2-1) proteins for the induction of humoral and cellular responses. We performed an open-label, dose escalation, phase 1 clinical trial in 42 healthy adults in which four different combinations of prime/boost vaccinations were investigated for safety and immunogenicity, including both intramuscular (IM) and intranasal (IN) administration of the adenovirus-vectored vaccine. The vaccines were safe and well tolerated, with the most common reported adverse events being mild injection site reactions. No vaccine-related serious adverse events occurred. RSV neutralizing antibody titers rose in response to IM prime with PanAd3-RSV and after IM boost for individuals primed by the IN route. Circulating anti-F immunoglobulin G (IgG) and IgA antibody-secreting cells (ASCs) were observed after the IM prime and IM boost. RSV-specific T cell responses were increased after the IM PanAd3-RSV prime and were most efficiently boosted by IM MVA-RSV. Interferon-γ (IFN-γ) secretion after boost was from both CD4(+) and CD8(+) T cells, without detectable T helper cell 2 (TH2) cytokines that have been previously associated with immune pathogenesis following exposure to RSV after the formalin-inactivated RSV vaccine. In conclusion, PanAd3-RSV and MVA-RSV are safe and immunogenic in healthy adults. These vaccine candidates warrant further clinical evaluation of efficacy to assess their potential to reduce the burden of RSV disease.
spellingShingle Green, C
Scarselli, E
Sande, C
Thompson, A
de Lara, C
Taylor, K
Haworth, K
Del Sorbo, M
Angus, B
Siani, L
Di Marco, S
Traboni, C
Folgori, A
Colloca, S
Capone, S
Vitelli, A
Cortese, R
Klenerman, P
Nicosia, A
Pollard, A
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title_full Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title_fullStr Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title_full_unstemmed Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title_short Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
title_sort chimpanzee adenovirus and mva vectored respiratory syncytial virus vaccine is safe and immunogenic in adults
work_keys_str_mv AT greenc chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT scarsellie chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT sandec chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT thompsona chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT delarac chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT taylork chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT haworthk chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT delsorbom chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT angusb chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT sianil chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT dimarcos chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT trabonic chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT folgoria chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT collocas chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT capones chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT vitellia chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT corteser chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT klenermanp chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT nicosiaa chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults
AT pollarda chimpanzeeadenovirusandmvavectoredrespiratorysyncytialvirusvaccineissafeandimmunogenicinadults